Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betamethasone + dexchlorpheniramine
- Development stage
- Phase 3
- Lead developer
- FutureChem
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Betamethasone + dexchlorpheniramine is a combination pharmaceutical product consisting of a synthetic corticosteroid (betamethasone) and a first-generation antihistamine (dexchlorpheniramine). This combination, widely known by the brand name Celestamine, is utilized for its synergistic anti-inflammatory and antiallergic properties in treating severe respiratory, dermatological, and ocular allergic conditions. In the specific context of clinical trials sponsored by FutureChem for prostate cancer diagnostics, such as the PSMA-targeting PET tracer [F-18]Florastamin (FC303), this combination is often employed as a premedication or supportive care intervention to prevent or manage potential hypersensitivity reactions associated with the administration of radiopharmaceuticals. Betamethasone provides potent glucocorticoid activity to suppress immune responses, while dexchlorpheniramine acts as a competitive H1-receptor antagonist to alleviate histamine-mediated symptoms.
- Brand names
- Celestamine
- Other names
- betamethasone and dexchlorpheniraminedexchlorpheniramine maleate + betamethasone
02
Targets
GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on betamethasone + dexchlorpheniramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betamethasone + dexchlorpheniramine.